Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia

Cancer

Volumn 117, Issue 1, 2011, Pages 116-124

  Wierda, William G ^a   Kipps, Thomas J ^b   Keating, Michael J ^a   Brown, Jennifer R ^c   Gribben, John G ^d   Browning, Mary ^e   Rassenti, Laura Z ^b   Greaves, Andrew W ^b   Neuberg, Donna ^c   O'Brien, Susan M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e GENZYME CORPORATION   (United States)

Author keywords

alemtuzumab; chronic lymphocytic leukemia; minimal residual disease; monoclonal antibody

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ALLERGIC RHINITIS; ANEMIA; ARTICLE; BACTEREMIA; CANCER REGRESSION; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CONSTIPATION; CONTROLLED CLINICAL TRIAL; COUGHING; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SELF ADMINISTRATION; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FLOW CYTOMETRY; HEADACHE; HEMOLYTIC ANEMIA; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PRURITUS; INJECTION SITE REACTION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; NIGHT SWEAT; PAIN; PATIENT DECISION MAKING; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; RASH; RIGOR; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

AGED; AGED, 80 AND OVER; ANEMIA; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; NEOPLASM, RESIDUAL; NEUTROPENIA;

EID: 78650692789     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25379     Document Type: Article

References (19)

1. Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008; 112: 975-980.
2. Wierda WG, Kipps TJ, Keating MJ., Novel immune-based treatment strategies for chronic lymphocytic leukemia. J Clin Oncol. 2005; 23: 6325-6332.
3. Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol. 2005; 23: 2971-2979.
4. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002; 99: 3554-3561.
5. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol. 2007; 25: 5616-5623.
6. Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2002; 100: 768-773.
7. Stilgenbauer S, Zenz T, Winkler D, et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2009; 27: 3994-4001.
8. O'Brien SM, Kantarjian HM, Thomas DA, et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer. 2003; 98: 2657-2663.
9. Chen L, Widhopf G, Huynh L, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2002; 100: 4609-4614.
10. Rebello P, Hale G., Pharmacokinetics of Campath-1H: assay development and validation. J Immunol Methods 260 (1-2): 285-302. 2002.
11. Rawstron AC, Villamor N, Ritgen M, et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia. 2007; 21: 956-964.
12. Kaplan EL, Meier P., Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
13. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer. 1977; 35: 1-39.
14. Wendtner CM, Ritgen M, Schweighofer CD, et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission - experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia. 2004; 18: 1093-1101.
15. Montillo M, Tedeschi A, Miqueleiz S, et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol. 2006; 24: 2337-2342.
16. Schweighofer CD, Ritgen M, Eichhorst BF, et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). Br J Haematol. 2009; 144: 95-98.
17. Lin TS, Donohue KA, Lucas MS, et al. Consolidation therapy with subcutaneous (SC) alemtuzumab results in severe infectious toxicity in previously untreated CLL patients who achieve a complete response (CR) after fludarabine and rituximab (FR) induction therapy: interim safety analysis of the CALGB study 10101 [abstract]. Blood. 2007; 110: 232a. Abstract 755.
18. O'Brien S, Ravandi F, Riehl T, et al. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood. 2008; 111: 1816-1819.
19. Hale G, Rebello P, Brettman LR, et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia after intravenous or subcutaneous routes of administration. Blood. 2004; 104: 948-955.